Nuvectis Pharma
NVCT
19.85
-0.44
-2.17%
Nuvectis Pharma
US · NVCT
#3557 by market cap
Listed 2022
19.85
-0.44
-2.17%
Live - 5344 symbols - heartbeat 394s ago
· 2026-10-08 10:11
After-hours
20.29
0.00%
- Market cap
- 647.98M
- P/E (TTM)i
- -15.04
- P/Bi
- 71.40
- EPSi
- -1.32
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on NVCT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.9 percentage points.
Institutional ownership
- Held by institutions
- 33.73% -4.91pp
- Institutions
- 105 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Individual/Insider34.92%
Mutual Fund19.25%
Hedge Fund9.06%
VC/PE Fund3.84%
Private Company1.07%
Public Company0.21%
Insurance Company0.13%
Government Pension Fund0.12%
Other31.35%
Top holders as of 2026-06-30
Ron Bentsur
11.32% · 3.69M sh
Charles Mosseri-Marlio
10.12% · 3.30M sh
Enrique Poradosu
5.54% · 1.81M sh
Shay Shemesh
5.50% · 1.79M sh
Tang Capital Management, LLC
4.76% · 1.55M sh
Soleus Capital Management, L.P.
4.60% · 1.50M sh
BlackRock
3.07% · 1.00M sh
Vanguard Capital Management, LLC
3.07% · 1.00M sh
Perceptive Advisors LLC
3.07% · 1.00M sh
Iridian Asset Management LLC
2.39% · 777.08K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
46 filings tracked · 44 buys · 1 sells
| Name | Role | Stake |
|---|---|---|
| Ron Bentsur | Chairperson & CEO | 11.32% |
| Charles Mosseri-Marlio | -- | 10.12% |
| Enrique Poradosu | Co-Founder, Executive VP, Chief Scientific & Business Officer | 5.54% |
| Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 5.50% |
| Michael Carson | Officer | 0.71% |
| Kenneth Hoberman | Independent Director | 0.52% |
| Matthew Kaplan | Independent Director | 0.49% |
| James Oliviero | Independent Director | 0.38% |
| Juan Sanchez | Director | 0.35% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-02 | Michael Carson | Officer | Other Acquisition | +30,000 | -- |
| 2026-06-29 | Ron Bentsur | Chairperson & CEO | Open Market Acquisition | +12,500 | $20.00 |
| 2026-06-29 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +50,000 | $18.32 |
| 2026-06-10 | James Oliviero | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Matthew Kaplan | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Juan Sanchez | Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Kenneth Hoberman | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-01-05 | Ron Bentsur | Chairperson & CEO | Other Acquisition | +150,000 | -- |
| 2026-01-05 | Enrique Poradosu | Co-Founder, Executive VP, Chief Scientific & Business Officer | Other Acquisition | +150,000 | -- |
| 2026-01-05 | Michael Carson | Officer | Other Acquisition | +61,200 | -- |
| 2026-01-05 | Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | Other Acquisition | +150,000 | -- |
| 2025-11-04 | Ron Bentsur | Chairperson & CEO | Open Market Acquisition | +5,000 | $5.72 |
| 2025-11-04 | Matthew Kaplan | Independent Director | Open Market Acquisition | +11,000 | $5.84 |
| 2025-11-04 | Juan Sanchez | Director | Open Market Acquisition | +13,000 | $5.79 |
| 2025-10-26 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +154,770 | $6.06–6.28 |
| 2025-09-21 | Juan Sanchez | Director | Other Acquisition | +30,000 | -- |
| 2025-09-21 | Juan Sanchez | Director | Initial Statement of Beneficial | 0 | -- |
| 2025-06-19 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +5,603 | $7.99 |
| 2025-06-17 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +33,442 | $8.05–8.11 |
| 2025-06-11 | James Oliviero | Independent Director | Other Acquisition | +30,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:11:01 · For reference only, not investment advice and not tailored to your situation.